Neumora receives FDA IND clearance for NMRA-266; starts Phase 1

Neumora Therapeutics, Inc.

NMRA-266 is a positive allosteric modulator of M4 muscarinic receptor, licensed from Vanderbilt University.
Phase 1 SAD/MAD study initiated in healthy adults after FDA IND clearance on Nov 27, 2023.
First clinical trial for NMRA-266; aims to evaluate safety, tolerability, and pharmacokinetics.
Neumora focuses on neuroscience; NMRA-266 could treat schizophrenia and other CNS disorders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.